Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Cellesce Announces License Agreement with Hubrecht Organoid Technology (HUB) for the Expansion of Breast Cancer Organoids at Scale

b3cnewswireApril 17, 2019

Tag: Cellesce , Hubrecht , HUB , breast , cancer

PharmaSources Customer Service